Moneyta · stock research · no sign-up needed
GSK
FollowFigures below come straight from SEC filings: every number is the company's own, on the record.
Revenue (FY FY2025)
$32.7B
Net income (FY FY2025)
$6.3B
as filed with the SEC
Institutions holding
1,053
+8 last quarter
Overview · GSK plc
GSK plc, together with its subsidiaries, engages in the research, development and manufacture of vaccines and specialty medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas,…
Management team
- Ms. Roanne Parry · Chief People OfficerFind on LinkedIn
- Ms. Emma Natasha Walmsley · Executive OfficerFind on LinkedIn
- Ms. Julie Belita Brown A.C.A. · CFO & Executive DirectorFind on LinkedIn
- Dr. Jesse L. Goodman M.D., M.P.H. · Scientific & Medical ExpertFind on LinkedIn
Start free to see the full management team.
Links open LinkedIn searches, not verified profiles. Team data from our market-data vendor's company profile.
What history says when its signals fire
Every signal Moneyta surfaces carries its full base-rate history: how often it beat the index, and how often it didn't. See the evidence
The desk's Snapshot
members see every cardRead the full desk report on GSK
Seven analysts, the debate, the risk review, every claim cited. And the same for every name you hold.
Free plan, no credit card required. Silver opens the full report, $19.99 a month. AI-written · every claim cites a source · Insight, not advice.
The full desk report
Seven AI analysts read the filings and argue both sides. What survives, with every claim cited, for members.
Who holds it, who's buying Gold
Full holder table, quarter-over-quarter flows, insider transactions, and the conviction screen.
Largest holder
Net flow last quarter
Insider buys, 90d
Further reading
Source: SEC EDGAR (XBRL company facts, form 13F-HR). Educational analysis of published data: insight, not advice.